IM Cannabis (IMCC) investor relations material

Executive summary

• Revenue for H1 2026 was $16.3M, down 35% year-over-year, with Q2 revenue at $7.6M, a 40% decline from Q2 2025, driven by shipment delays, product mix, pricing, and reduced imports due to cash constraints.

• Gross profit for H1 2026 was $2.9M (18% margin), down from $6.9M (27% margin) in H1 2025; Q2 gross profit was $1.5M (20% margin), down from $3.4M (27% margin) in Q2 2025.

• Net loss for H1 2026 was $6.9M ($0.85/share), compared to a net loss of $0.02M ($0.01/share) in H1 2025; Q2 net loss was $4.4M ($0.47/share), versus $0.2M ($0.09/share) in Q2 2025.

• The company continued to focus on operational efficiency, cost-saving measures, and restructuring to address ongoing liquidity challenges.

Financial highlights

• Revenue for H1 2026: $16.3M (down 35% YoY); Q2 2026: $7.6M (down 40% YoY).

• Gross profit for H1 2026: $2.9M (18% margin); Q2 2026: $1.5M (20% margin).

• Operating loss for H1 2026: $3.8M; Q2 2026: $2.1M.

• Net loss for H1 2026: $6.9M ($0.85/share); Q2 2026: $4.4M ($0.47/share).

• Cash as of June 30, 2026: $1.6M; total assets: $24.7M; total liabilities: $30.3M; shareholders' deficit: $5.5M.

Outlook and guidance

• Management continues to pursue cost-saving initiatives, operational efficiencies, and new business activities to improve liquidity and long-term growth.

• The company is exploring additional capital raising and debt financing, but there is no assurance of success.

• Uncertainties remain regarding the ability to continue as a going concern due to negative working capital and ongoing losses.